|
No dosage adjustment is necessary in patients with renal impairment, hepatic impairment, or for elderly patients. Doses higher than 40 mg/ day have not been studied in hepatically-impaired patients. No dosage adjustment is necessary in patients undergoing hemodialysis.
PROTONIX delayed-release Tablets should be swallowed whole, with or without food in the stomach. If patients are unable to swallow a 40 mg tablet, two 20 mg tablets may be taken. Concomitant administration of antacids does not affect the absorption of PROTONIX.
Patients should be cautioned that PROTONIX delayed-release Tablets should not be split, chewed or crushed. HOW SUPPLIED PROTONIX (pantoprazole sodium) Delayed-Release Tablets are supplied as 40 mg yellow oval biconvex delayed-release tablets imprinted with PROTONIX (brown ink) on one side. Text Continues Below
They are available as follows: NDC 0008-0841-10 bottles of 100 NDC 0008-0841-81 bottles of 90 NDC 0008-0841-91 bottles of 1000 NDC 0008-0841-99 carton of 10 Redipak blister strips of 10 tablets each PROTONIX is supplied as 20 mg yellow oval biconvex delayed-release tablets imprinted with P20 (brown ink) on one side.
They are available as follows: NDC 0008-0843-81 bottles of 90 Storage Store PROTONIX delayed-release Tablets at 20 –25 C (68 –77 F); excursions permitted to 15 -30 C (59 -86 F).
[See USP Controlled Room Temperature]. U. S. Patent No. 4,758,579
Packaged by Wyeth Laboratories A Wyeth-Ayerst Company Philadelphia, PA 19101 under license from ALTANA Pharma D78467 Konstanz, Germany
W10438C006 ET01 Rev 02/ 04 16
Page: << Prev | 1 | 2
|
.gif)
